Home » Stocks » NCNA

NuCana PLC (NCNA)

Stock Price: $5.26 USD -0.12 (-2.23%)
Updated Mar 2, 2021 4:00 PM EST - Market closed
Market Cap 248.49M
Revenue (ttm) n/a
Net Income (ttm) -33.71M
Shares Out 32.94M
EPS (ttm) -0.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 2
Last Price $5.26
Previous Close $5.38
Change ($) -0.12
Change (%) -2.23%
Day's Open 5.40
Day's Range 5.21 - 5.48
Day's Volume 209,385
52-Week Range 4.04 - 10.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 1 month ago

Find out what led to the biotech industry's biggest gains.

Other stocks mentioned: ALDX, LXRX
GlobeNewsWire - 1 month ago

Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patients who had Progressed on Prior Fluoropyrimidine Therapy

Zacks Investment Research - 1 month ago

NuCana (NCNA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

GlobeNewsWire - 2 months ago

Pharmaceutical Executive Brings a Wealth of Experience to NuCana's Board of Directors

GlobeNewsWire - 3 months ago

Acelarin plus Cisplatin's High Objective Response Rate and Favorable Safety Profile Confirmed

GlobeNewsWire - 3 months ago

Completed Successful $ 8 0 million Public Offering

GlobeNewsWire - 3 months ago

EDINBURGH, United Kingdom, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...

GlobeNewsWire - 3 months ago

EDINBURGH, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...

Zacks Investment Research - 3 months ago

NuCana (NCNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

GlobeNewsWire - 4 months ago

Abingworth Makes Significant Investment in NuCana’s Recent $80 million Public Offering Abingworth Makes Significant Investment in NuCana’s Recent $80 million Public Offering

Zacks Investment Research - 5 months ago

NuCana (NCNA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

GlobeNewsWire - 5 months ago

Encouraging Efficacy Signals Observed in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer in the Phase Ib Study of NUC-3373 (NuTide:302)

GlobeNewsWire - 5 months ago

EDINBURGH, United Kingdom, Sept. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with c...

GlobeNewsWire - 5 months ago

EDINBURGH, United Kingdom, Sept. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with c...

GlobeNewsWire - 5 months ago

EDINBURGH, United Kingdom, Sept. 16, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with c...

GlobeNewsWire - 6 months ago

EDINBURGH, United Kingdom, Aug. 19, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2020 and provided an update on its br...

Zacks Investment Research - 6 months ago

NuCana (NCNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 9 months ago

NuCana (NCNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor of NuCana

Zacks Investment Research - 9 months ago

Top Ranked Momentum Stocks to Buy for May 28th

Other stocks mentioned: AAWW, AXU, GMDA
Zacks Investment Research - 9 months ago

The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.

Other stocks mentioned: CYAD, DXCM, HOLX, TDOC
GlobeNewsWire - 9 months ago

Clinical Studies Re-Opened to New Patient Enrollment Following Temporary Pause Due to COVID-19 Pandemic

GlobeNewsWire - 9 months ago

EDINBURGH, United Kingdom, May 18, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in multiple clinical studies following the temp...

GlobeNewsWire - 9 months ago

EDINBURGH, U.K., May 05, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in NuTide:121, its ongoing global Phase III study of Acel...

GlobeNewsWire - 11 months ago

EDINBURGH, United Kingdom, April 02, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) has been closely monitoring the potential impact of the COVID-19 pandemic on its operations and announ...

GlobeNewsWire - 11 months ago

Confirmed Complete Response and Two Partial Responses Achieved in Heavily Pre-treated Population

GlobeNewsWire - 11 months ago

EDINBURGH, United Kingdom, March 04, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) ha...

Zacks Investment Research - 1 year ago

We expect NuCana (NCNA) to provide updates on its pipeline when it releases fourth-quarter results.

GlobeNewsWire - 1 year ago

Global NuTide:121 Study Is Enrolling up to 828 Patients and Comparing Acelarin plus Cisplatin to Gemcitabine plus Cisplatin

GlobeNewsWire - 1 year ago

NUC-3373: Favorable Pharmacokinetic Profile Demonstrated

GlobeNewsWire - 1 year ago

Global NuTide:121 Study will Enroll up to 828 Patients and Compare Acelarin plus Cisplatin to Gemcitabine plus Cisplatin

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in NuCana plc (NCNA).

GlobeNewsWire - 1 year ago

EDINBURGH, United Kingdom, Aug. 29, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, wi...

GlobeNewsWire - 1 year ago

EDINBURGH, United Kingdom, Aug. 27, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, wi...

GlobeNewsWire - 1 year ago

Numerous Clinical Data Announcements and Study Initiations Expected in 2019

Zacks Investment Research - 1 year ago

NuCana (NCNA) suspends patient enrollment in the phase III study on Acelarin, currently evaluated for treating patients with metastatic pancreatic cancer, who were unfit for combination chemot...

Market Watch - 1 year ago

Shares of NuCana Plc fell 21% on Tuesday after the company announced it had suspended the enrollment of new patients in a late-stage trial of a pancreatic cancer drug.

GlobeNewsWire - 1 year ago

Imbalances in Prognostic Factors May Have Impacted Analysis

GuruFocus - 1 year ago

Falling Knives are companies whose share prices have fallen more than 59% over the past year, generating the interest of investors as they can make huge gains if they bounce back.

Other stocks mentioned: GLYC
Zacks Investment Research - 1 year ago

NuCana (NCNA) doses the first patient in a phase I study on NUC-7738, which is being evaluated for the treatment of advanced solid tumors.

Zacks Investment Research - 1 year ago

The FDA confers an orphan drug designation on NuCana's (NCNA) pipeline candidate, Acelarin, for treating patients with biliary tract cancer

Seeking Alpha - 1 year ago

NCNA’s ProTide technology has been used to develop drugs like Sovaldi and Genvoya.

About NCNA

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase Ib and Phase III clinical trials for the treatment of patients with biliary tract cancer; a Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trial for the treatment of patients with biliary cancer; and Phase III clinical... [Read more...]

Industry
Biotechnology
IPO Date
Sep 28, 2017
CEO
Hugh Griffith
Employees
29
Stock Exchange
NASDAQ
Ticker Symbol
NCNA
Full Company Profile

Financial Performance

Financial numbers in millions GBP.
Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for NuCana stock is "Strong Buy." The 12-month stock price forecast is 1,155.19, which is an increase of 21,861.79% from the latest price.

Price Target
$1,155.19
(21,861.79% upside)
Analyst Consensus: Strong Buy